Leerink Partners initiated coverage on AnaptysBio with a new price target
$ANAB
Biotechnology: Pharmaceutical Preparations
Health Care
Leerink Partners initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $47.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/22/2024 | $55.00 | Buy | H.C. Wainwright |
| 7/19/2024 | $29.00 → $69.00 | Neutral → Overweight | JP Morgan |
| 4/16/2024 | $47.00 | Outperform | Leerink Partners |
| 4/11/2024 | $56.00 | Overweight | Wells Fargo |
| 3/12/2024 | $20.00 → $34.00 | Neutral → Outperform | Wedbush |
| 2/26/2024 | $55.00 | Buy | BTIG Research |
| 2/21/2024 | $50.00 | Buy | Stifel |
| 2/16/2024 | $80.00 | Overweight | Piper Sandler |
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics. AnaptysBio has a pipeline of checkpoint agonists, including rosnilimab, a PD-1 agonist in development for rheumatoid arthritis (RA) and ulcerative colitis (UC), and ANB032, a B and T cell lymphocyte attenuator (BTLA) agonist in development for atopic dermatitis (AD). In Phase 1, rosnilimab showed a 90% reduction of T cell proliferation, inflammatory cytokine secretion and PD-1(high) T cells and demonstrated favorable safety. Related: Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Trigge
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on AnaptysBio (NASDAQ:ANAB) with a Buy rating and announces Price Target of $55.
JP Morgan analyst Anupam Rama upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Overweight and raises the price target from $29 to $69.
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
H.C. Wainwright initiated coverage of AnaptysBio with a rating of Buy and set a new price target of $55.00
JP Morgan upgraded AnaptysBio from Neutral to Overweight and set a new price target of $69.00 from $29.00 previously
Leerink Partners initiated coverage of AnaptysBio with a rating of Outperform and set a new price target of $47.00
SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
SC 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
SC 13D/A - ANAPTYSBIO, INC (0001370053) (Subject)
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis (RA) in February 2025Phase 1 trial initiated in healthy volunteers for ANB033, our anti-CD122 antagonistReiterating cash runway through year-end 2026 SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update. "We remain confident in the
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate and Time – Wednesday, Nov. 13, 2024 at 1:30pm ET / 10:30am PT Stifel 2024 Healthcare Conference, New York, NY Format – Fireside chat and one-on-one investor meetingsDate and Time – Tue
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences: 2024 Wells Fargo Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate and Time – Thursday, Sept. 5, 2024 at 10:15am ET / 7:15am PT Stifel 2024 Virtual Immunology and Inflammation Summit Format – Fireside chatDate and Time – Tuesday, Sept. 17, 2024 at 1:30pm ET /
EFFECT - ANAPTYSBIO, INC (0001370053) (Filer)
424B5 - ANAPTYSBIO, INC (0001370053) (Filer)
S-3 - ANAPTYSBIO, INC (0001370053) (Filer)
4 - ANAPTYSBIO, INC (0001370053) (Issuer)
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.
After more than 15 years serving on AnaptysBio's Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors. "We are excited to welcome John to Anaptys' Board of Directors as chairman. With more than 25 years of diverse experience across the biopharmaceutical landscape, John brings a track record of substantial accomplishment across our sector as a biotech CEO a
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023Initiating a global Phase 2b trial for rosnilimab, a PD-1 agonist antibody, in rheumatoid arthritis (RA) later in Q3 2023 and a second Phase 2 trial, in an indication yet to be announced, by year-end 2023Daniel Faga appointed to the permanent position of president and chief executive officerReiterating cash runway through year-end 2026 and updated expected year-end 2023 cash and investments of $380 – $395 million SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused o
Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for Investigative Dermatology (ISID) Annual Meeting poster presentation for ANB032, a BTLA agonist, Phase 1 dataInitiating a global Phase 2b trial to treat rheumatoid arthritis in Q3 2023 and a second Phase 2 trial, in an indication to be announced, by year-end 2023 with rosnilimab, a PD-1 agonistReiterating cash runway through year-end 2026 with expected year-end 2023 cash and investments of $370 – $385 million SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage b